Fertility company INVO Bioscience has received FDA clearance to expand the use of its INVOcell device, paving the way for improved patient outcomes in infertility treatment. The device, known for its affordability and effectiveness, can now be utilized for a 5-day incubation period, similar to conventional in vitro fertilization (IVF) procedures. Steve Shum, CEO of INVO Bioscience, shares: “This is a momentous…
Fertility clinic network Kindbody is announcing the addition of Kindlabs, a new division to conduct in-house genetic testing, expanding Kindbody’s range of comprehensive services to offer seamless, end-to-end care. The Kindlabs launch follows last year’s acquisition of Phosphorus Labs, a preventative genomics company. Kindlabs will operate from its state-of-the-art 8,000 square foot laboratory located in Secaucus, New Jersey. It’s headed by Dr.…
Fertifa, a London-based startup, helping European businesses to provide fertility and reproductive health benefits to employees has recently raised £5M in funding from Notion Capital and Triple Point Ventures. The round also saw participation from Conviction, Calm/Storm, Tiny.vc, EQT Foundation and a host of angel investors, along with the return of existing investors. Launched in 2019 by Tony Chen and Nick Kuan,…
Celmatix, a biotech firm specializing in women’s health, has announced progress in their oral fertility drug program. The program’s primary objective is to substitute follicle stimulating hormone (FSH) injections, commonly used in in vitro fertilization (IVF) and egg freezing protocols, with an oral alternative. This New York-based company aims to make ovulation induction more efficient, specifically for women with conditions like polycystic…
Embie Clinic is on a mission to optimize fertility treatments with personalized, connected care. Its platform empowers fertility clinics worldwide with real-time insights while reducing administrative burdens. As a top patient-facing fertility treatment app, Embie supports 48K+ women across 120 countries today. New research presented by Embie Clinic at the 39th Annual European Society of Human Reproduction and Embryology (ESHRE) meeting today…
May Health, a clinical-stage medical device company focusing on polycystic ovary syndrome (PCOS), presented promising results from the ULTRA-EU and ULTRA-US feasibility clinical trials for its Ovarian Rebalancing treatment at the 39th Annual European Society of Human Reproduction and Embryology (ESHRE) meeting. The trials demonstrated the treatment’s safety and effectiveness in inducing ovulation in women with PCOS-related infertility. The company also received…
Israeli fertility company Fairtility has announced the launch of CHLOE OQ, a tool aimed at fertility preservation, at the 39th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Copenhagen today. The newly unveiled tool provides Oocyte Quality Insights, predicting the potential of an oocyte (egg cell) to develop into the blastocyst stage after fertilization, a crucial aspect…
Oova, a women’s health and fertility startup, has secured $10.3 million in Series A funding for its at-home fertility tracking approach. The company offers the Oova Kit, an FDA-registered at-home urine test that measures luteinizing hormone and progesterone. The test provides personalized analytics and real-time action plans, helping women identify fertile days and confirm ovulation. Although focused on fertility for now, the…
